Guido Ghilardi

1.5k total citations
19 papers, 95 citations indexed

About

Guido Ghilardi is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Guido Ghilardi has authored 19 papers receiving a total of 95 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Guido Ghilardi's work include CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Guido Ghilardi is often cited by papers focused on CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Guido Ghilardi collaborates with scholars based in United States, Switzerland and Italy. Guido Ghilardi's co-authors include B. Gerber, Davide Rossi, Georg Stüssi, Marco Ruella, Stephen J. Schuster, Luca Mazzucchelli, Christoph Röcken, Thomas Fehr, Clemens B. Caspar and Peter Brændstrup and has published in prestigious journals such as Blood, British Journal of Haematology and Cancers.

In The Last Decade

Guido Ghilardi

18 papers receiving 93 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guido Ghilardi United States 6 47 36 27 16 16 19 95
Chih-Hsun Yang Taiwan 5 25 0.5× 42 1.2× 11 0.4× 29 1.8× 10 0.6× 7 169
Anne Lazareth France 7 14 0.3× 17 0.5× 28 1.0× 28 1.8× 24 1.5× 13 88
Sigrún Reykdal Iceland 5 25 0.5× 27 0.8× 27 1.0× 22 1.4× 38 2.4× 6 127
Zsolt Nagy Hungary 5 32 0.7× 18 0.5× 13 0.5× 31 1.9× 14 0.9× 15 85
Idoya Zazpe Spain 9 81 1.7× 15 0.4× 56 2.1× 21 1.3× 9 0.6× 18 161
Sébastien Delbès France 3 165 3.5× 43 1.2× 25 0.9× 7 0.4× 24 1.5× 5 184
Rachel B. Blaustein United States 3 54 1.1× 31 0.9× 8 0.3× 9 0.6× 10 0.6× 4 144
Himanshu Chheda Finland 4 33 0.7× 29 0.8× 27 1.0× 9 0.6× 47 2.9× 4 124
Margareth Macro France 4 32 0.7× 29 0.8× 23 0.9× 43 2.7× 15 0.9× 7 94
Carolyn Stewart United States 4 48 1.0× 120 3.3× 19 0.7× 10 0.6× 6 0.4× 8 145

Countries citing papers authored by Guido Ghilardi

Since Specialization
Citations

This map shows the geographic impact of Guido Ghilardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Ghilardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Ghilardi more than expected).

Fields of papers citing papers by Guido Ghilardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guido Ghilardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Ghilardi. The network helps show where Guido Ghilardi may publish in the future.

Co-authorship network of co-authors of Guido Ghilardi

This figure shows the co-authorship network connecting the top 25 collaborators of Guido Ghilardi. A scholar is included among the top collaborators of Guido Ghilardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guido Ghilardi. Guido Ghilardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ghilardi, Guido, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, et al.. (2025). Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review. Journal for ImmunoTherapy of Cancer. 13(1). e009349–e009349. 1 indexed citations
2.
Chong, Elise A., Elise A. Chong, Sunita D. Nasta, et al.. (2024). Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 30(7). 726.e1–726.e8. 4 indexed citations
3.
Ghilardi, Guido, et al.. (2024). Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies. Blood. 144(Supplement 1). 4848–4848. 1 indexed citations
4.
Snook, Adam E., Guido Ghilardi, Steven Yang, et al.. (2023). Senza5 TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity. Blood. 142(Supplement 1). 3462–3462. 1 indexed citations
5.
Cohen, Ivan, Ki Hyun Kim, Scott A. Jenks, et al.. (2023). Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor. Blood. 142(Supplement 1). 1020–1020. 1 indexed citations
6.
Ghilardi, Guido, Puneeth Guruprasad, Mathew G. Angelos, et al.. (2023). Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies. Blood. 142(Supplement 1). 102–102.
7.
Porazzi, Patrizia, Yusuke Isshiki, Guido Ghilardi, et al.. (2023). Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality. Blood. 142(Supplement 1). 1018–1018. 2 indexed citations
8.
Ghilardi, Guido, Luciano Cascione, Darius Juškevičius, et al.. (2022). Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers. 14(4). 1018–1018. 10 indexed citations
9.
Gerber, B., et al.. (2022). Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report. Journal of Medical Case Reports. 16(1). 113–113. 2 indexed citations
10.
11.
Ruella, Marco, Mireia Uribe‐Herranz, Silvia Beghi, et al.. (2021). Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects. Blood. 138(Supplement 1). 163–163. 1 indexed citations
12.
Ghilardi, Guido, Giuseppe Colucci, Luigia Elzi, et al.. (2021). Long-Term Evaluation of Antiphospholipid Antibodies in Patients with COVID-19. SSRN Electronic Journal. 1 indexed citations
13.
Ghilardi, Guido, Peter Brændstrup, Elise A. Chong, et al.. (2020). CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. British Journal of Haematology. 193(3). 449–465. 11 indexed citations
14.
Manz, Markus G., Christine Waibel, Clemens B. Caspar, et al.. (2019). Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematological Oncology. 37(5). 595–600. 24 indexed citations
15.
Ghilardi, Guido, Georg Stüssi, Luca Mazzucchelli, et al.. (2019). Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). Amyloid. 26(3). 173–174. 15 indexed citations
16.
Monti, Marco De, et al.. (1997). [Plasma-cell granuloma of the sigmoid colon concomitant with adenocarcinoma of the cecum. Viewpoint for debate, literature review on pseudotumors, idiopathic colitis and cancer].. PubMed. 68(2). 245–51. 3 indexed citations
17.
Pagani, G., et al.. (1990). Medical management of acromegaly: effects of SMS 201-995 in 30 patients.. PubMed. 24(1-2). 175–85. 7 indexed citations
18.
Camboni, M. G., et al.. (1985). Gastrointestinal transit in hyperthyroid patients before and after propranolol treatment.. PubMed. 80(7). 550–2. 3 indexed citations
19.
Francalanci, Simona & Guido Ghilardi. (1960). [The behavior of the C-reactive protein in some primary and metastatic tumors].. PubMed. 15. 174–80. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chih-Hsun Yang Breakdown of academic impact, for papers by Anne Lazareth Breakdown of academic impact, for papers by Sigrún Reykdal Breakdown of academic impact, for papers by Zsolt Nagy Breakdown of academic impact, for papers by Idoya Zazpe Breakdown of academic impact, for papers by Sébastien Delbès Breakdown of academic impact, for papers by Rachel B. Blaustein Breakdown of academic impact, for papers by Himanshu Chheda Breakdown of academic impact, for papers by Margareth Macro Breakdown of academic impact, for papers by Carolyn Stewart
Rankless by CCL
2026